Results 61 to 70 of about 36,471 (149)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies

open access: yesInternational Journal of COPD, 2019
Jill A Ohar,1 Alyssa Bowling,2 Thomas Goodin,2 Barry Price,2 Ayca Ozol-Godfrey,2 Sanjay Sharma,2 Shahin Sanjar2 1Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
Ohar JA   +6 more
doaj  

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD

open access: yesInternational Journal of COPD, 2018
Colin Reisner,1,2 James Pearle,3 Edward M Kerwin,4 Earl St Rose,1 Patrick Darken1 1Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA; 2AstraZeneca, Gaithersburg, MD, USA; 3California Research Medical Group, Inc., Fullerton, CA, USA ...
Reisner C   +4 more
doaj  

Aerosol bronchodilator administration in ventilator circuits [PDF]

open access: bronze, 1978
Stephen C. Allen, Rae Morris, C. C. Wise
openalex   +1 more source

Spirometric Indices after Bronchodilator Test in Obstructive Lung Disease

open access: yesActa Medica Iranica, 2010
Bronchial responsiveness to bronchodilator medications is usually tested to establish reversibility of airflow obstruction. Among the various tests to establish bronchodilator response, FEV1, FEF25-75% or FEF50%, and FVC are the most widely used.
Amir Houshang Mehrparvar   +2 more
doaj  

Home - About - Disclaimer - Privacy